Skip to main content
SpringerLink
Log in

IGF 1 and IGF 2

  • Living reference work entry
  • First Online:
Cancer Therapeutic Targets

  • 156 Accesses

Abstract

Insulin-like growth factor-1 (IGF-1) and IGF-2 are circulating peptide growth factor hormones important in normal growth and development. Their biological effects are mediated by specific cell surface receptors, the type I IGF receptor (IGF1R) and the insulin receptor. In cancer, preclinical and epidemiological evidence support a role for these growth factors in regulating cancer risk and tumor biology. Thus, neutralization of these growth factors could play a role in cancer prevention and therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell. 1993;75:73–82.

    Article  CAS  PubMed  Google Scholar 

  • Bell GI, Merryweather JP, Sanchez-Pescador R, Stempien MM, Priestley L, Scott J, Rall LB. Sequence of a cDNA clone encoding human preproinsulin-like growth factor II. Nature. 1984;310:775–7.

    Article  CAS  PubMed  Google Scholar 

  • Divisova J, Kuiatse I, Lazard Z, Weiss H, Vreeland F, Hadsell DL, Schiff R, Osborne CK, Lee AV. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat. 2006;98:315–27.

    Article  CAS  PubMed  Google Scholar 

  • Domene HM, Hwa V, Argente J, Wit JM, Camacho-Hubner C, Jasper HG, Pozo J, van Duyvenvoorde HA, Yakar S, Fofanova-Gambetti OV, Rosenfeld RG. Human acid-labile subunit deficiency: clinical, endocrine and metabolic consequences. Horm Res. 2009;72:129–41.

    Article  CAS  PubMed  Google Scholar 

  • Dransfield DT, Cohen EH, Chang Q, Sparrow LG, Bentley JD, Dolezal O, Xiao X, Peat TS, Newman J, Pilling PA, Phan T, Priebe I, Brierley GV, Kastrapeli N, Kopacz K, Martik D, Wassaf D, Rank D, Conley G, Huang Y, Adams TE, Cosgrove L. A human monoclonal antibody against insulin-like growth factor-II blocks the growth of human hepatocellular carcinoma cell lines in vitro and in vivo. Mol Cancer Ther. 2010;9:1809–19.

    Article  CAS  PubMed  Google Scholar 

  • Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A, Vigneri R. Insulin receptor isoform A, a newly recognized, high-affinity insulin- like growth factor II receptor in fetal and cancer cells. Mol Cell Biol. 1999;19:3278–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Frystyk J, Freda P, Clemmons DR. The current status of IGF-I assays – a 2009 update. Growth Horm IGF Res. 2010;20:8–18.

    Article  CAS  PubMed  Google Scholar 

  • Govoni KE, Baylink DJ, Mohan S. The multi-functional role of insulin-like growth factor binding proteins in bone. Pediatr Nephrol. 2005;20:261–8.

    Article  PubMed  PubMed Central  Google Scholar 

  • Goya M, Miyamoto S, Nagai K, Ohki Y, Nakamura K, Shitara K, Maeda H, Sangai T, Kodama K, Endoh Y, Ishii G, Hasebe T, Yonou H, Hatano T, Ogawa Y, Ochiai A. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res. 2004;64:6252–8.

    Article  CAS  PubMed  Google Scholar 

  • Gualberto A, Dolled-Filhart M, Hixon M, Christensen J, Rimm D, Lee A, Wang Y, Pollak M, Paz-Ares L, Karp D. Molecular bases for sensitivity to figitumumab (CP-751,871) in NSCLC. J Clin Oncol. 2009;27:Abstr 8091.

    Google Scholar 

  • Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW, Hwang D, Martin-Montalvo A, Saavedra J, Ingles S, de Cabo R, Cohen P, Longo VD. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med. 2011;3:70ra13.

    Article  PubMed  PubMed Central  Google Scholar 

  • Hu Q, Gao F, Tian W, Ruteshouser EC, Wang Y, Lazar A, Stewart J, Strong LC, Behringer RR, Huff V. Wt1 ablation and Igf2 upregulation in mice result in Wilms tumors with elevated ERK1/2 phosphorylation. J Clin Invest. 2011;121:174–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jansen M, van Schaik FM, Ricker AT, Bullock B, Woods DE, Gabbay KH, Nussbaum AL, Sussenbach JS, Van den Brande JL. Sequence of cDNA encoding human insulin-like growth factor I precursor. Nature. 1983;306:609–11.

    Article  CAS  PubMed  Google Scholar 

  • Kaneda A, Wang CJ, Cheong R, Timp W, Onyango P, Wen B, Iacobuzio-Donahue CA, Ohlsson R, Andraos R, Pearson MA, Sharov AA, Longo DL, Ko MS, Levchenko A, Feinberg AP. Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk. Proc Natl Acad Sci U S A. 2007;104:20926–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kleinberg DL, Wood TL, Furth PA, Lee AV. Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev. 2008;30:51–74.

    Article  PubMed  Google Scholar 

  • Martin JL, Baxter RC. Signalling pathways of insulin-like growth factors (IGFs) and IGF binding protein-3. Growth Factors. 2011;29:235–44.

    Article  CAS  PubMed  Google Scholar 

  • Mauras N. Growth hormone and sex steroids. Interactions in puberty. Endocrinol Metab Clin North Am. 2001;30:529–44.

    Article  CAS  PubMed  Google Scholar 

  • Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363:1346–53.

    Article  CAS  PubMed  Google Scholar 

  • Schally AV, Varga JL, Engel JB. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab. 2008;4:33–43.

    Article  CAS  PubMed  Google Scholar 

  • Steuerman R, Shevah O, Laron Z. Congenital IGF-I deficiency tends to confer protection against post-natal development of malignancies. Eur J Endocrinol. 2011;164:485–9.

    Article  CAS  PubMed  Google Scholar 

  • Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer. 2009;16:1103–23.

    Article  CAS  PubMed  Google Scholar 

  • Yin D, Vreeland F, Schaaf LJ, Millham R, Duncan BA, Sharma A. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clin Cancer Res. 2007;13:1000–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Masonic Cancer Center, University of Minnesota, 420 Delaware Street SE, MMC 194; Suite 14-106 Phillips-Wangenste, Minneapolis, MN, 55455, USA

    Douglas Yee

Authors
  1. Douglas Yee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Douglas Yee .

Editor information

Editors and Affiliations

  1. Georgetown University Div. Hematology & Oncology, Washington, District of Columbia, USA

    John L. Marshall

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this entry

Cite this entry

Yee, D. (2013). IGF 1 and IGF 2. In: Marshall, J. (eds) Cancer Therapeutic Targets. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6613-0_4-2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-6613-0_4-2

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, New York, NY

  • Online ISBN: 978-1-4614-6613-0

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation